{"id":"placebo-extended-release-oxycodone-pills","safety":{"commonSideEffects":[{"rate":null,"effect":"Placebo response (pain relief, symptom improvement)"},{"rate":null,"effect":"Nocebo effects (adverse events attributed to inert substance)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Placebo extended-release oxycodone pills are inert formulations designed to mimic the appearance and administration schedule of active oxycodone while containing no opioid or other therapeutic agent. They are used in randomized controlled trials to establish baseline efficacy attributable to expectation, ritual, and natural disease progression, allowing researchers to isolate the true pharmacological effects of the active drug.","oneSentence":"A placebo formulation containing no active pharmaceutical ingredient, used as a control in clinical trials to measure the non-pharmacological effects of treatment.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:42:09.978Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Clinical trial control arm for oxycodone efficacy studies"}]},"trialDetails":[{"nctId":"NCT04132011","phase":"PHASE4","title":"Dosing Intervals of Opioid Medication for Chronic Pain","status":"WITHDRAWN","sponsor":"University Health Network, Toronto","startDate":"2019-05-01","conditions":"Chronic Pain","enrollment":""},{"nctId":"NCT00955110","phase":"PHASE4","title":"Study to Compare Oxymorphone Extended-Release (Opana ER) Versus Oxycodone Controlled-Release (Oxycontin)","status":"COMPLETED","sponsor":"Endo Pharmaceuticals","startDate":"2009-06","conditions":"Healthy","enrollment":78},{"nctId":"NCT00414453","phase":"PHASE4","title":"Trial of Analgesia With Lidocaine or Extended-release Oxycodone for Neuropathic Pain Treatment in Multiple Sclerosis","status":"TERMINATED","sponsor":"University of Rochester","startDate":"2007-01","conditions":"Neuropathic Pain, Chronic Pain, Multiple Sclerosis","enrollment":19}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Placebo pill"],"phase":"marketed","status":"active","brandName":"Placebo extended-release oxycodone pills","genericName":"Placebo extended-release oxycodone pills","companyName":"University of Rochester","companyId":"university-of-rochester","modality":"Small molecule","firstApprovalDate":"","aiSummary":"A placebo formulation containing no active pharmaceutical ingredient, used as a control in clinical trials to measure the non-pharmacological effects of treatment. Used for Clinical trial control arm for oxycodone efficacy studies.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}